Where Does Prescribed Medical Cannabis Come From – Is It Imported?
Medical cannabis has become a topic of increasing interest across the UK, both in the media and among patients seeking alternative treatments. But one common question remains: where does prescribed medical cannabis actually come from? Is it cultivated locally, or mostly imported from abroad? And how does the UK health system regulate and supply this emerging therapy?
In this comprehensive guide, we’ll explore the sourcing of medical cannabis within the UK and beyond, clarify the role of authorised importers and manufacturers, explain the eligibility criteria for patients, and outline how specialists prescribe this treatment with careful clinical judgement.
What Is Medical Cannabis and Who Can Get It?
Medical cannabis refers to cannabis-based products prescribed by doctors to treat specific health conditions, such as chronic pain, epilepsy, or multiple sclerosis symptoms, when conventional treatments have not been effective. Unlike recreational cannabis, medical cannabis is tightly regulated and only available on prescription from suitably qualified specialists.
Eligibility After Conventional Treatments
The UK’s National Institute for Health and Care Excellence (NICE) and NHS guidelines recommend that medical cannabis is typically considered only after patients have tried and not benefited sufficiently from standard therapies. This means patients must usually:
- Have a confirmed diagnosis of a qualifying condition.
- Complete or be actively managing conventional treatment options (e.g., anti-epileptics, painkillers, muscle relaxants).
- Experience ongoing symptoms or side-effects that might justify trying medical cannabis as an additional option.
This stepwise approach helps ensure medical cannabis is reserved for cases where the potential benefits outweigh the risks and uncertainties involved.
How Medical Cannabis Is Prescribed in the UK
Since November 2018, UK law allows certain specialist doctors to prescribe cannabis-based medicinal products (CBMPs) on the NHS or privately. However, general practitioners (GPs) cannot prescribe these products.
Instead, patients require referral to a consultant or specialist clinician with specific expertise and registration on the Home Office specialist register. This specialist authorisation ensures appropriate patient selection and careful monitoring of outcomes and side effects.
Specialist Consultation via Private Clinics
Accessing prescribed medical cannabis on the NHS remains very limited, often restricted to highly specific cases. Consequently, many patients turn to private clinics specialising in cannabinoid medicine to obtain consultations and prescriptions.
These clinics provide experienced clinicians who understand evolving evidence, can discuss personalised risk-benefit profiles, and offer a supported pathway to treatment. Private prescribing also often means greater product choice but can involve substantial costs borne directly by patients.
Where Does Medical Cannabis Come From? UK Sourcing and Importing
One of the most common misconceptions is that prescribed medical cannabis is grown widely within the UK or sourced from domestic farms. The reality is more complex.
Authorised Manufacturers Cannabis UK
Within the UK, there is currently only one authorised licensed producer of medical cannabis:
- British Cannabis Ltd: Granted a licence to cultivate and manufacture cannabis medicinal products for UK supply, British Cannabis is a pioneering domestic cultivator. Their operations comply with Home Office licenses and Good Manufacturing Practice (GMP) standards, ensuring medicinal quality and safety.
Despite this presence, British Cannabis currently supplies a small fraction of the total demand for medical cannabis products in the UK.
Authorised Importers Cannabis UK
The majority of prescribed medical cannabis products come from carefully regulated importers authorised by the UK government. These importers source products from established manufacturers overseas who comply with stringent regulatory frameworks. Importers must:
- Hold valid Home Office licences for controlled drugs importation.
- Work only with manufacturers meeting GMP and quality standards.
- Ensure full traceability and compliance with UK medical product regulations.
Some of the main countries producing authorised medical cannabis for the UK market include the Netherlands, Canada, and Germany, where established cannabis pharmaceutical firms operate large GMP-certified facilities.
Why Is Importing Predominant?
- Scale and expertise: Overseas manufacturers have longer experience and larger scale facilities dedicated to producing consistent, standardised cannabis medicinal products.
- Legal and licensing landscape: While UK cultivation licences exist, the regulated environment is still developing, making import a faster way to meet patient needs.
- Product diversity: Importers supply a wider range of medicines — oils, capsules, sprays — with varied cannabinoid profiles tailored to patients’ specific conditions.
Typical UK Medical Cannabis Products and Their Costs
Medical cannabis products prescribed in the UK come in various forms such as:
- Cannabis-based oils and tinctures (e.g. Sativex, Epidyolex, or bespoke formulations)
- Capsules and tablets
- Inhalers (less common)
Prices vary depending on the product strength, quantity, and supplier. For example, a typical 10 ml bottle of a cannabis oil prescribed privately might cost between £150 and £350, with ongoing monthly costs potentially reaching £1,500 depending on dosage.
Product Form Typical Dose Approximate Private Cost (GBP) Cannabis Oil (Standardised) Oral oil 5-20 ml daily £150 - £350 per 10 ml bottle Sativex® Mouth spray 4-12 sprays daily £400 - £600 for a 10 ml spray vial Epidyolex® (CBD oil for epilepsy) Oral solution Weight adjusted Varies; NHS funded in some cases
The Specialist-Only Prescribing Register
In the UK, medical cannabis prescribing is tightly controlled via a specialist-only register maintained by the Home Office in collaboration with the General Medical Council (GMC). Only consultants with expertise in relevant clinical areas — such as neurology, pain management, or palliative care — and who have completed specialist training on CBMPs are permitted to prescribe.
This specialist-only approach is intended to:
- Ensure prescribers understand the nuances of cannabis pharmacology and potential interactions.
- Allow proper patient assessment including consideration of psychological and physical risks.
- Enable detailed monitoring and clinical audits of outcomes to build evidence for future guidance.
Risk-Benefit Clinical Judgement in Prescribing Medical Cannabis
Medical cannabis is not a universal cure, nor free from risks. The decision to prescribe it relies heavily on a careful clinical risk-benefit analysis, considering individual patient circumstances and evidence for specific conditions.
Factors Considered
- Potential therapeutic benefit: Will cannabis products offer symptom improvement where other treatments have failed?
- Risks: Side effects, mental health impacts, dependency risk, interactions with other medications.
- Patient history: Previous substance use, comorbidities, age, and personal preferences.
- Product quality: Only authorised cannabis products with defined cannabinoid content and GMP certification are prescribed.
- Legal and ethical considerations: Prescribers remain accountable through registration and must adhere to guidelines.
This judicious approach is why medical cannabis will usually be considered only after other treatments have been tried — to maximise patient safety while exploring new therapeutic options.
Summary
In summary, prescribed medical cannabis in the UK mostly comes from a combination of a small but growing domestic cultivation industry and a regulated network of authorised overseas manufacturers and importers. These products are tightly controlled in quality and supply, ensuring patient safety.
Access remains specialist-led, with eligibility contingent on prior conventional treatments, and prescriptions issued only by qualified consultants registered on the specialist prescribing register. Clinical risk-benefit judgement is fundamental when considering medical cannabis, reflecting the evolving evidence and individual patient needs.
If you’re considering medical cannabis, a specialist consultation is essential to discuss eligibility, sourcing, treatment options, and costs, particularly through private clinics offering expertise in this area.
Share This Article
Found this article useful? Share it on your favourite social networks and help inform others:
- Tumblr
- Skype
- Messenger
- Telegram
- VKontakte
- Odnoklassniki
Replace "YOURARTICLEURL" in these links with the actual URL of this article before https://dotimes.co.uk/medical-cannabis-in-the-uk-a-clear-guide-to-how-legal-prescriptions-work/ sharing.
